Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 206

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Vascular toxic effects of cancer therapies

Open access
Herrmann, Joerg · 2020 · Nature Reviews Cardiology

Abstract

Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the second most common group. The range of cancer therapies with a vascular toxicity profile and the clinical spectrum of vascular toxic effects are quite broad. Historically, venous thromboembolism has received the greatest attention but, over the past decade, the arterial toxic effects, which can present as acute vasospasm, acute thrombosis and accelerated atherosclerosis, of cancer therapies have gained greater recognition. This Review focuses on these types of cancer therapy-related arterial toxicity, including their mechanisms, and provides an update on venous thromboembolism and pulmonary hypertension associated with cancer therapies. Recommendations for the screening, treatment and prevention of vascular toxic effects of cancer therapies are outlined in the context of available evidence and society guidelines and consensus statements. The shift towards greater awareness of the vascular toxic effects of cancer therapies has further unveiled the urgent needs in this area in terms of defining best clinical practices. Well-designed and well-conducted clinical studies and registries are needed to more precisely define the incidence rates, risk factors, primary and secondary modes of prevention, and best treatment modalities for vascular toxicities related to cancer therapies. These efforts should be complemented by preclinical studies to outline the pathophysiological concepts that can be translated into the clinic and to identify drugs with vascular toxicity potential even before their widespread clinical use. This Review outlines the mechanisms of cancer therapy-related vascular toxicity and provides recommendations for screening, treatment and prevention in the context of available evidence and society guidelines. The Review focuses on the main types of arterial toxicity, acute vasospasm, acute thrombosis and accelerated atherosclerosis, and provides an update on cancer therapy-related venous thromboembolism and pulmonary hypertension. Vascular toxic effects of cancer therapies include arterial and venous events and affect the systemic and pulmonary circulations. Cancer therapy-related arterial toxicities can present as acute vasospasm, acute thrombosis and accelerated atherosclerosis. The management of cancer therapy-related vascular toxicities is directed towards the underlying pathological mechanism; therefore, defining the underlying mechanism is a central element. The best modes of pre-therapy screening, surveillance and prevention are yet to be defined. Clinical studies and registries are needed to define more precisely the risk, risk factors and risk management of the vascular toxic effects of cancer therapies. Experimental studies should provide insight into the pathophysiological mechanisms of cardiovascular toxic effects of cancer therapies, which might also lead to an improved understanding of cardiovascular diseases in general. Vascular toxic effects of cancer therapies include arterial and venous events and affect the systemic and pulmonary circulations. Cancer therapy-related arterial toxicities can present as acute vasospasm, acute thrombosis and accelerated atherosclerosis. The management of cancer therapy-related vascular toxicities is directed towards the underlying pathological mechanism; therefore, defining the underlying mechanism is a central element. The best modes of pre-therapy screening, surveillance and prevention are yet to be defined. Clinical studies and registries are needed to define more precisely the risk, risk factors and risk management of the vascular toxic effects of cancer therapies. Experimental studies should provide insight into the pathophysiological mechanisms of cardiovascular toxic effects of cancer therapies, which might also lead to an improved understanding of cardiovascular diseases in general.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41569-020-0347-2

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 206

Metadata

Authors
Herrmann, J.
Venue
Nature Reviews Cardiology
Published
2020-03-26
Volume
17
Issue
8
Pages
503-522
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
OpenAlex
W3013925558
Cited by
206
References
16
FWCI
6.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular toxic effects of cancer therapies. https://app.cochat.ai/papers/10.1038/s41569-020-0347-2
The paper
Herrmann, J. (2020). Vascular toxic effects of cancer therapies. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-020-0347-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.